Literature DB >> 7688673

Changes in natural immunity during the course of HIV-1 infection.

B G Brenner1, C Gryllis, M Gornitsky, M A Wainberg.   

Abstract

The role of natural killer (NK) and lymphokine-activated killer (LAK) cell-mediated cytotoxicity in AIDS has yet to be established. The objective of this study was to determine inducible LAK cell responses at different stages of HIV-1 infection, and specifically to establish the participation of CD8 lymphocytes in these responses. Peripheral blood lymphocytes (PBL) were isolated from healthy seronegative (CDC-0) subjects and HIV-1+ individuals who were clinically asymptomatic (Centre for Disease Control group 2, CDC-2) or symptomatic (CDC-4) with regard to secondary opportunistic infection (OI). LAK cells were generated upon incubation of PBL with IL-2 and their cytolysis of K562 and U-937 targets was determined using chromium release assays. The role of CD8+ lymphocytes as progenitors and effectors of these LAK cell responses was determined by immunomagnetic depletion of CD8+ cells from precursor PBL and LAK cells, respectively. LAK cell-mediated cytotoxicities in HIV-1-infected individuals were reduced compared with seronegative controls without any corresponding changes in the relative proportions of CD56+ (NK) cells among groups. Depletions of CD8+ subsets from either PBL or LAK cells dramatically reduced total LAK cytotoxic responses and LAK activities per unit CD56+ cell in the OI-/CDC-2 seropositive population. No corresponding changes in LAK activities in seronegative control or HIV+/OI+/CDC-4 groups were observed. Levels of LAK activity against K562 targets in CDC-0/HIV- and CDC-4/HIV+ groups correlated with the percentage of CD56+ LAK cells; corresponding LAK activity in the CDC-2/HIV+ group correlated with the percentage of both CD56+ and CD8+ subsets. These findings suggest that adaptive changes in non-MHC restricted cytotoxic responses occur in HIV-1 individuals at early stages post-HIV infection, before the onset of opportunistic infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688673      PMCID: PMC1554830          DOI: 10.1111/j.1365-2249.1993.tb07956.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  46 in total

1.  Mechanism of defective natural killer cell activity in patients with AIDS is associated with defective distribution of tubulin.

Authors:  M C Sirianni; S Soddu; W Malorni; G Arancia; F Aiuti; S Soddus
Journal:  J Immunol       Date:  1988-04-15       Impact factor: 5.422

2.  Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells.

Authors:  F W Ruscetti; J A Mikovits; V S Kalyanaraman; R Overton; H Stevenson; K Stromberg; R B Herberman; W L Farrar; J R Ortaldo
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

Review 3.  Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality.

Authors:  E A Grimm
Journal:  Biochim Biophys Acta       Date:  1986-12-17

4.  Characterization of HNK-1+ (Leu-7) human lymphocytes. I. Two distinct phenotypes of human NK cells with different cytotoxic capability.

Authors:  T Abo; M D Cooper; C M Balch
Journal:  J Immunol       Date:  1982-10       Impact factor: 5.422

5.  Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity.

Authors:  H F Pross; M G Baines; P Rubin; P Shragge; M S Patterson
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

6.  Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity.

Authors:  J D Katz; R Mitsuyasu; M S Gottlieb; L T Lebow; B Bonavida
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

7.  In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.

Authors:  J H Phillips; B T Gemlo; W W Myers; A A Rayner; L L Lanier
Journal:  J Clin Oncol       Date:  1987-12       Impact factor: 44.544

8.  Peripheral blood natural killer cell activity in human breast cancer patients and its modulation by T-cell growth factor and autologous plasma.

Authors:  B G Brenner; S Benarrosh; R G Margolese
Journal:  Cancer       Date:  1986-08-15       Impact factor: 6.860

9.  Lymphokine-activated killer cells. Analysis of progenitors and effectors.

Authors:  J R Ortaldo; A Mason; R Overton
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

10.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

Authors:  J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

View more
  15 in total

1.  Reversal of human immunodeficiency virus type 1 protein-induced inhibition of natural killer cell activity by alpha interferon and interleukin-2.

Authors:  M P Nair; S A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

2.  Differential expression of perforin in cytotoxic lymphocyte in HIV/AIDS patients of China.

Authors:  Wang Qi; Jiang Yongjun; Wang Yanan; Zhang Zining; Han Xiaoxu; Liu Jing; Shang Hong
Journal:  J Clin Immunol       Date:  2006-06-13       Impact factor: 8.317

3.  Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection.

Authors:  Bluma G Brenner; Jean-Pierre Routy; Marco Petrella; Daniela Moisi; Maureen Oliveira; Mervi Detorio; Bonnie Spira; Vidal Essabag; Brian Conway; Richard Lalonde; Rafick-Pierre Sekaly; Mark A Wainberg
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

4.  Natural-killer cell-derived cytolytic molecules in HIV-associated pulmonary tuberculosis-role of exogenous interleukins.

Authors:  P V Ramana Rao; S Ramanavelan; S Rajasekaran; Alamelu Raja
Journal:  J Clin Immunol       Date:  2010-03-13       Impact factor: 8.317

5.  Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy.

Authors:  Antonio Valentin; Margherita Rosati; Daniel J Patenaude; Angelos Hatzakis; Leondios G Kostrikis; Marios Lazanas; Kathleen M Wyvill; Robert Yarchoan; George N Pavlakis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

Review 6.  Dendritic cells and natural killer cells in the pathogenesis of HIV infection.

Authors:  Claudio Fortis; Guido Poli
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

7.  Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection.

Authors:  S J Lin; R L Roberts; B J Ank; Q H Nguyen; E K Thomas; E R Stiehm
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

8.  Interleukin-2-inducible natural immune (lymphokine-activated killer cell) responses as a functional correlate of progression to AIDS.

Authors:  B G Brenner; M Gornitsky; M A Wainberg
Journal:  Clin Diagn Lab Immunol       Date:  1994-09

9.  Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity.

Authors:  Wassim M Ballan; Bien-Aimee N Vu; Brian R Long; Christopher P Loo; Jakob Michaëlsson; Jason D Barbour; Lewis L Lanier; Andrew A Wiznia; Jacobo Abadi; Glenn J Fennelly; Michael G Rosenberg; Douglas F Nixon
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

10.  Combined in vitro effect of marijuana and retrovirus on the activity of mouse natural killer cells.

Authors:  J Ongrádi; S Specter; A Horváth; H Friedman
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.